Press Releases
See the latest from ProtoKinetix
Review our press releases for information about our current research, recent findings and key milestones. If you want to follow along our journey of cell survival, subscribe to our newsletter so you never miss an update.
Jul 09, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has reached the mid-point of 3rd stage of testing in retinal cell replacement therapy at the University of British Columbia. […]
Jun 07, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction […]
May 30, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) today announces that it will hold the first in a series of Town Hall Meetings. This meeting is being held […]
May 09, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has […]
May 06, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has been requested by OTC Markets Group to comment on certain recent promotional activity encouraging investors to purchase the Company’s […]
Apr 23, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates it’s stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British […]
Request More Information
Talk to a member of the ProtoKinetix team to learn more about our research and results.
ProtoKinetix, Inc.